A new remedy can benefit diabetics

The results of the experience have shown that people with type 1 diabetes who need to lose weight can benefit from the popular “Simajlotide”, which are compounds of the “Bulkid-1-Peptide-1” peptide, which is currently approved for type 2 diabetic. “Simaglotide” is the active ingredient in the real estate “Ozimbek”, and “Ribellesus” for diabetes of (Novo Nordsk), as well as the treatment of weight loss “wigofi”. The study supervisor Ferral Shah at the Faculty of Medicine at the University of Indiana said at the American Diabetes Association meeting in Chicago that 36 patients injected weekly with ‘Simajlotide’ with the usual insulin spent longer in the extent of the targeted sugar in the blood, and more than 36 similar patients lost a fake Drug with a drug drug in the first clinical trial and the drug “Novo Nordk” on Type 1 -Dieden and lost to testing the drug “Novo Nordk” on Type 1 Difes and testing obesity. All patients used automatic insulin connection systems, and the BMI has 30 or higher, which is included in the extent of obesity. A third of the patients in the “Simaglotide” group reached all the three goals of the study, which is the blood sugar level in the target, range from 70 to 180 milligrams in the disylre, low blood sugar and low body weight with at least 5%, and the average weight loss with ‘simaglotide’ was nine kilograms. The study report published in the “Evidins” Journal of the New England Journal of Medicine reported that no one in the fictional drug group did not achieve all three goals. Shah said in a statement: “We hope our experience will encourage the sector to conduct an organizational approval experience so that this medicine can be provided as an insulin treatment assistant to improve the management of type 1 diabetes,” Shah said in a statement.